MUSE Microscopy adds PathGroup founder Ben Davis to board

MUSE Microscopy named PathGroup founder Ben W. Davis to its board as the company pushes ahead with its slide-free pathology imaging platform. The move gives MUSE a veteran diagnostics operator as it moves from technical development toward clinical validation and commercialization.

Why it matters: - Ben Davis brings four decades of experience across clinical practice, laboratory operations, company building, and board governance. - MUSE Microscopy is trying to move SmartPath from development into clinical validation and broader market execution. - The board appointment adds leadership experience in scaling diagnostics businesses, which can matter when hospitals and labs evaluate new workflows.

What happened: - MUSE Microscopy appointed Ben W. Davis, M.D., founder of PathGroup and current PathGroup board member, to its board of directors on Sept. 14, 2026. - Davis founded PathGroup in 1996 and served as longtime chief executive officer. - PathGroup has grown into a national provider of anatomic, clinical, molecular, and digital pathology services. - PathGroup now serves more than 250 hospitals and health systems, plus thousands of physician groups and surgery centers.

The details: - MUSE Microscopy develops slide-free, tissue-to-digital pathology technology under its SmartPath MUSE Technology platform. - Davis will advise the company on corporate governance, clinical and laboratory workflow integration, commercialization, health-system adoption, strategic partnerships, and responsible operating scale. - MUSE said Davis’s background in scaling a physician-led diagnostics organization aligns with its plan to introduce a new tissue-imaging workflow to pathologists, laboratories, and health systems. - Chief Executive Officer Matthew Nuñez said Davis understands what pathologists need, what health systems require before adopting new technology, and what it takes to build infrastructure and commercial discipline at scale. - Chairman Gary Fudge said Davis will help sharpen priorities, strengthen governance, and support the company’s next phase. - MUSE’s commercial product, SmartPath MUSE Technology, is a slide-free direct-to-digital imaging platform intended to provide rapid diagnostic information through digital imaging. - MUSE says the system is under development and pending U.S. Food and Drug Administration clearance or approval. - The product is not cleared or approved for clinical diagnostic use in the United States. - MUSE specializes in Microscopy with Ultraviolet Surface Excitation, or MUSE, for diagnostic assistance in pathology and research applications.

Between the lines: - The appointment signals that MUSE is prioritizing operating credibility as much as technical progress. - Bringing in a founder who scaled a national pathology business suggests MUSE expects adoption challenges to center on workflow, trust, and commercialization, not just imaging performance. - The board addition also reflects a common late-stage move: pairing product development with leaders who have already built regulated health-care businesses.

What's next: - MUSE is expected to continue clinical validation and prepare for broader market execution. - Davis is likely to play a role in helping the company frame partnerships and hospital adoption as it advances SmartPath. - MUSE will also need to navigate FDA clearance or approval before any U.S. clinical diagnostic use.

The bottom line: - MUSE is adding a seasoned pathology executive to help turn a promising imaging platform into a business hospitals and labs can actually adopt.